<DOC>
	<DOCNO>NCT02264054</DOCNO>
	<brief_summary>Study investigate metabolism , pharmacokinetic , safety tolerability talsaclidine .</brief_summary>
	<brief_title>Pharmacokinetics Talsaclidine After Administration Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male Age range 50 65 year Participants within 20 % normal weight ( BrocaIndex ) Written informed consent accordance Good Clinical Practice local legislation Results medical examination laboratory test ( especially indicate liver malfunction ) judge clinical investigator differ significantly normal clinical value Known gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Disease central nervous system ( epilepsy ) psychiatric disorder Known history orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( ≥ 24 hour ) within one month enrolment study Intake drug might influence result trial week previous start study Participation another study investigational drug within last 2 month precede study Unability refrain smoke study day Volunteers smoke 10 cigarette ( 3 cigar pipe ) per day Volunteers drink 40 g alcohol per day Volunteers dependent drug Blood donation ( ( ≥ 100 ml ) within last 4 week Excessive physical activity ( e.g . competitive sport ) within last week study</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>